As the healthcare and supplement industries experience seismic shifts—driven by new U.S. tariffs, growing scrutiny on Big Pharma, and rising pharmaceutical costs—Biologic Pharmamedical remains ...

U.S. investors and large pharmaceutical companies are increasingly doing deals in China as the country's biopharma sector transforms.

With a 10% tariff making Chinese products costlier, US importers may turn to Indian companies as cost-effective alternatives.

The US Food and Drug Administration (FDA) has issued several warning letters to pharmaceutical manufacturers in India and ...

President Trump’s tariffs in China are in place and hitting all products imported from the country — including a number of pharmaceutical drugs that Americans rely upon. Chinese imports ...

CFO Vanessa Kanu reported Q4 adjusted EBITDA of $195 million, representing a 9% increase year-over-year. She attributed the 27% increase in adjusted diluted EPS to strong margins and a lower tax rate ...

Half a world away from Washington, Asia’s corporate titans are coming to grips with the new, or perhaps all too familiar, ...

Ansell has moved to expand its manufacturing presence beyond China, to countries including India and Sri Lanka.

Public health experts worry the FDA workforce will be slashed, impeding the ability of the agency to review new medicines ...

BD affects millions but remains misunderstood, underdiagnosed, and underfunded. Researchers are working to change this by ...

The Trump Administration's 10% tariff on all Chinese imports took effect on Feb. 4. Many unknowns remain, but Americans will ...